Anika Therapeutics commenced initial U.S. launch of TACTOSET injectable HA-enhanced therapy to treat bone voids and other bone defects of the skeletal system.
The U.S. Patent Trial and Appeal Board denied Stryker's request for an inter partes review of challenged claims in a suit pertaining to KFx Medical's suture anchors.
The first 30 patients received treatment in DiscGenics' first-in-human U.S. clinical study of IDCT injectable disc cell therapy for mild to moderate degenerative disc disease.
Preliminary study results indicate that X-BOLT Orthopaedics' X-BOLT device for hip fracture repair demonstrated a cut-out rate of 0.8% in a population of 476 patients, and performed as well as a hip sliding screw in measures such as quality of life, mortality, revision, etc.